one of my major takeaways from dr. kim's interview was his long term view of the potential worth of the company. sound like he wasn't going to be interested in buyout offers. wants to do more licensing and partnerships with major pharma. while this isn't a new position, i thought he was very clear in his detail. as he's stated before; inovio has a value currently around $100 million yet he said it has the potential to be worth $30 billion. i am very positive in the management of this company!
...on the other hand, Dr. Kim as a expert in this sector knows very well how things are:
"WSJ: What are some other developments in the vaccine industry?
Mr. Kim: Large pharmaceutical companies that traditionally didn’t have vaccine businesses are expanding in that area through different ways. One way is to make acquisitions AstraZeneca AZN.LN +0.22%, for example, has purchased a relatively large vaccine company called Medimmune Johnson & Johnson JNJ -0.09% has acquired Dutch biotechnology firm Crucell."
(Crucell was another company which collaborated with Bill & Melinda Gates Foundation, like INO)
"WSJ: Are you working with large pharmaceutical companies?
Mr. Kim: We have had product-based license agreements with Merck and Wyeth, which is now part of Pfizer PFE -0.34%. We are in discussions with other major players for some of our newer products."
So, Dr. Kim wants to do more licensing and partnerships but I think he also knows that a acquisition proposal will knock his door sooner or later...